Advanced Enzyme Technologies Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing an Advanced Enzyme Technologies target price for 2027 should start with where the stock sits today. At Rs 269.60 on 9 October 2026, it is 35.7% below its 52-week high of Rs 419.00 and 7.0% above its 52-week low of Rs 251.95. That range spans 66% from low to high, so the entry point matters as much as the Advanced Enzyme Technologies price forecast itself.

This article builds the Advanced Enzyme Technologies share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 298 base case and the Rs 361 bull case were reached, along with a downside risk level of Rs 212.

Click Here – Get Free Investment Predictions

Advanced Enzyme Technologies Stock Analysis: Company Overview and Key Stats

Advanced Enzyme Technologies (NSE: ADVENZYMES) has a market capitalisation of Rs 2,967 crore. In FY26 it reported revenue of Rs 780.59 crore and net profit of Rs 173.61 crore. The table collects the figures the Advanced Enzyme Technologies share price target is built on.

Metric	Value
Company	Advanced Enzyme Technologies
NSE Ticker	ADVENZYMES
CMP (9 October 2026)	Rs 269.60
52-Week High	Rs 419.00
52-Week Low	Rs 251.95
Market Cap	Rs 2,967 crore
PE Ratio (TTM)	17.28
Industry PE	37.59
Price to Book	1.82
Return on Equity	10.34%
Debt to Equity	0.02
EPS (TTM)	Rs 15.34
Dividend Yield	2.02%
12-Month Base Target	Rs 298
Bull Case	Rs 361
Downside Risk Level (not a target)	Rs 212

Why Is Advanced Enzyme Technologies Share Price Target Set at Rs 298 for 2027?

The base-case Advanced Enzyme Technologies stock target of Rs 298 applies a PE multiple of 17.28 to a forward EPS estimate of Rs 17.24. That EPS assumes 12.4% yearly growth, the pace from FY24 to FY26, and puts the target 10.5% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Advanced Enzyme Technologies Target Price: Five Years of Results

Advanced Enzyme Technologies grew revenue from Rs 535.80 crore in FY22 to Rs 780.59 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew more slowly, from Rs 123.80 crore to Rs 173.61 crore (8.8% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	535.80	123.80	10.68	1.00
FY23	566.09	103.87	9.45	1.00
FY24	660.53	136.95	11.92	5.10
FY25	669.95	133.97	11.71	5.20
FY26	780.59	173.61	15.06	5.35

FY26 revenue growth was 16.5%, faster than the four-year average of 9.9%, and net profit moved up 29.6%. EPS rose from Rs 11.92 in FY24 to Rs 15.06 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Advanced Enzyme Technologies converted 22.2% of FY26 revenue into net profit, against 20.0% in FY25, within a five-year range of 18.3% to 23.1%. EBITDA margin was 35.3% in FY26 versus 34.0% in FY25.

In the June 2026 quarter, revenue was Rs 202.81 crore, up 4.1% from the same quarter a year earlier, while net profit of Rs 38.59 crore was down 4.6%. EBITDA came in at Rs 63.99 crore, down 2.0% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.02, and shareholders' equity grew from Rs 1,140 crore in FY22 to Rs 1,683 crore in FY26. Operating cash flow in FY26 was Rs 156.78 crore against capital expenditure of Rs 52.38 crore, leaving free cash flow of Rs 104.40 crore, or 3.5% of the current market capitalisation. In FY25 free cash flow was Rs 107.72 crore.

Valuation Check for the Advanced Enzyme Technologies Stock Target: PE, Price to Book and ROE

At a PE of 17.28 against an industry PE of 37.59, Advanced Enzyme Technologies trades at a discount to its industry. Price to book is 1.82 on a book value of Rs 145.72 per share, and return on equity is 10.34%. A PE of 17.28 equals an earnings yield of 5.8%, and the FY26 dividend of Rs 5.35 per share gives a yield of 2.02%.

Shareholding Pattern and Institutional Holding

Promoters held 43.24% of Advanced Enzyme Technologies in June 2026, and promoter holding rose from 43.08% in June 2025 to 43.24% in June 2026. Foreign institutional investors (FII) held 26.71% and domestic institutions (DII) held 4.78%, which puts total institutional holding at 31.49%. FII holding rose from 23.46% in June 2025 to 26.71% in June 2026. Public shareholders own the remaining 25.27%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Advanced Enzyme Technologies Share Price Targets for the Short Term and 12 Months

Short Term Advanced Enzyme Technologies Stock Target Levels: Technical Setup

At Rs 269.60 on 9 October 2026, Advanced Enzyme Technologies trades below its 50-day simple moving average of Rs 296.53 and below its 200-day exponential moving average of Rs 313.86. The 14-day RSI reads 30.8, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 296.53 (50-day simple moving average) and the nearest support is Rs 251.95 (52-week low). A sustained move above Rs 296.53 would improve the short-term setup, while a close below Rs 251.95 would shift attention to the next support.

12 Month Advanced Enzyme Technologies Target Price for 2027

The 12-month target for Advanced Enzyme Technologies is Rs 298: forward EPS of Rs 17.24 at a PE of 17.28. That is 10.5% above Rs 269.60. It would still leave the stock 28.9% below its 52-week high of Rs 419.00.

How EPS Growth and PE Multiple Change the Advanced Enzyme Technologies Target Price

EPS Growth	PE 13.82	PE 17.28	PE 19.87
0.0% (EPS Rs 15.34)	Rs 212	Rs 265	Rs 305
12.4% (EPS Rs 17.24)	Rs 238	Rs 298	Rs 343
18.4% (EPS Rs 18.16)	Rs 251	Rs 314	Rs 361

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Advanced Enzyme Technologies price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Advanced Enzyme Technologies Stock Target in 2027

Bull Case Rs 361

The bull case Advanced Enzyme Technologies price target needs EPS growth of 18.4%, which lifts forward EPS to Rs 18.16, and a PE multiple that rises 15% to 19.87. That gives Rs 361, 33.9% above the current price and below the 52-week high of Rs 419.00.

Downside Risk Level Rs 212

The downside risk level is not a target. It assumes EPS stays flat at Rs 15.34 and the PE falls 20% to 13.82. That gives Rs 212, 21.4% below the current price and below the 52-week low of Rs 251.95.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	18.4%	19.87	Rs 361	+33.9%
Base Case	12.4%	17.28	Rs 298	+10.5%
Downside Risk	0.0%	13.82	Rs 212	-21.4%

Key Risks to the Advanced Enzyme Technologies Target Price for 2027

Growth Slowdown Risk for the Advanced Enzyme Technologies Price Target

Revenue in the June 2026 quarter was up 4.1% year on year, and FY26 revenue growth was 16.5%. If growth slows from here, the EPS estimate behind the Advanced Enzyme Technologies stock target will need revising.

Liquidity and Size Risk

Advanced Enzyme Technologies has a market capitalisation of Rs 2,967 crore. Institutional holding is 31.49%, and promoters hold 43.24%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 22.2% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 17.28 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 13.82 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 35.7% below its 52-week high, with an RSI of 30.8 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Advanced Enzyme Technologies

Start with the live price and volume. Any Advanced Enzyme Technologies share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 269.60 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Advanced Enzyme Technologies' PE, ROE, debt and shareholding in one place.

Check Advanced Enzyme Technologies fundamentals on the Univest Screener

Then compare the three Advanced Enzyme Technologies target price scenarios with your own view. If you expect EPS growth below 12.4%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Advanced Enzyme Technologies live price and get daily stock recommendations.

Conclusion

The Advanced Enzyme Technologies share price target for 2027 is Rs 298 in the base case, with Rs 361 as the bull case. The support for that view is arithmetic you can check: EPS grew 12.4% a year over FY24 to FY26, and the stock trades at a PE of 17.28. The risks are equally concrete, including a stock that sits 35.7% below its 52-week high and a downside scenario that cuts the price 21% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Advanced Enzyme Technologies Share Price Target 2027

What is the Advanced Enzyme Technologies share price target for 2027?

Ans. The base-case Advanced Enzyme Technologies share price target for 2027 is Rs 298, with Rs 361 as the bull case. The downside risk level, which is not a target, is Rs 212. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Advanced Enzyme Technologies share price today?

Ans. As of 9 October 2026, 12:52 PM IST, Advanced Enzyme Technologies trades at Rs 269.60, up 1.77% on the day. The 52-week range is Rs 251.95 to Rs 419.00.

Is Advanced Enzyme Technologies a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 12.4% a year over FY24 to FY26, but the stock is 35.7% below its 52-week high. Whether Advanced Enzyme Technologies fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Advanced Enzyme Technologies shares?

Ans. The bull case target is Rs 361, which assumes 18.4% EPS growth and a PE of 19.87. The downside risk level is Rs 212, which assumes flat EPS and a PE of 13.82. It marks a risk, not a target.

What are the main risks to the Advanced Enzyme Technologies price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 2,967 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Advanced Enzyme Technologies and how does it compare with the industry?

Ans. The PE ratio of Advanced Enzyme Technologies is 17.28 against an industry PE of 37.59. Price to book is 1.82 and return on equity is 10.34%. The base case in the Advanced Enzyme Technologies price target holds this PE constant.

Who owns Advanced Enzyme Technologies, and what is the promoter holding?

Ans. Promoters held 43.24% of Advanced Enzyme Technologies in June 2026. FII held 26.71%, DII held 4.78% and the public held 25.27%.

What were Advanced Enzyme Technologies' latest quarterly results?

Ans. In the June 2026 quarter, Advanced Enzyme Technologies reported revenue of Rs 202.81 crore (up 4.1% year on year) and net profit of Rs 38.59 crore (down 4.6%).